Do you want to read an article? Please log in or register.
Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS
Macular DiseasesRetinal Diseases
Related content
COMMENTED
Macular Diseases
Curcumin-Based Treatment for Macular Edema from Uncommon Etiologies: Efficacy and Safety Assessment
★ 2
Recommended by
Dr Katarzyna Konieczka, Faculty Member
★ 2
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
J Med Food.
Ferrara M, Allegrini D, Sorrentino T, Sborgia G, Parmeggiani F, Borgia A, Romano MR
doi: 10.1089/jmf.2019.0241.
COMMENTED
Macular Diseases
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM
doi: 10.1001/jamaophthalmol.2020.5053
Macular DiseasesRetinal Diseases
Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study
JAMA Ophthalmol.
Karst SG, Deak GG, Gerendas BS, Waldstein SM, Lammer J, Simader C, Guerin T, Schmidt-Erfurth UM
doi: 10.1001/jamaophthalmol.
Macular Diseases
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
Ophthalmology
Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J; TREND Study Group
doi: 10.1016/
Macular Diseases
Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials
JAMA Ophthalmol.
Zarbin MA, Dunger-Baldauf C, Haskova Z, Koovejee P, Mousseau MC, Margaron P, Snow H, Beaumont PE, Staurenghi G, Francom S
doi: 10.1001/
Macular Diseases
Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion
Ophthalmol Retina.
Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z
doi: 10.1016/j.oret.2019.08.009.
Macular DiseasesRetinal Diseases
Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE
Ophthalmology.
Reddy RK, Pieramici DJ, Gune S, Ghanekar A, Lu N, Quezada-Ruiz C, Baumal CR
doi: 10.1016/
Cornea and Corneal DiseasesConjunctivitisBlindness and Vision ImpairmentFlammer SyndromeGlaucoma and Ocular PressureLensesMacular DiseasesOcular OncologyRetinal DiseasesSurgery and InterventionUveitisCataractsDry Eye Disease
Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study
Acta Ophthalmol
Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y, Zhang J, Dong F, Xu X, Weisberger A
doi: 10.1111/aos.14588
Macular Diseases
RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study
Retina.
Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, Wykrota H, Sharma S, Dunger-Baldauf C, Lacey S, Macfadden W, Mitchell P
doi: 10.1097/IAE.0000000000002670.